Purpose To determine the incidence of nephrogenic systemic fibrosis (NSF) in patients with
renal disease who received gadobenate dimeglumine at a single medical center. Materials …

Among the currently available brain tumor imaging, advanced MR imaging techniques, such
as diffusion-weighted MR imaging and perfusion MR imaging, have been used for solving …

Purpose To determine the ability of different types of gadolinium-based contrast agents
(GBCAs) to stimulate fibroblast proliferation in monolayer cell culture. Materials and Methods …

Purpose: Investigation of dissociated versus chelated gadolinium (Gd) in plasma, skin, and
bone of rats with impaired renal function after administration of ionic macrocyclic (gadoterate …

In 1997, a new fibrosing skin disorder became apparent among patients with renal disease.
Nephrogenic systemic fibrosis, as this disorder has come to be known, has recently been …

Purpose To examine the positive reporting bias regarding the link with gadolinium (Gd)
exposure and nephrogenic systemic fibrosis (NSF) in patients with renal impairment. This …

Nephrogenic systemic fibrosis is a new disease whose incidence has peaked and receded
over the past decade. It occurs in the presence of significant renal impairment, either acute …

NSF develops when 'the perfect storm'of factors is present: unstable/pro-inflammatory GBC
agent exposure, advanced kidney disease, and unique patient factors. Recognizing this …

Nephrogenic systemic fibrosis (NSF) is a disease seen exclusively in patients with
decreased renal function. The use of gadolinium-based contrast agents (GBCAs) has a …

Nephrogenic systemic fibrosis (NSF) is a disabling and potentially fatal disease that has
been associated with gadolinium‐based contrast (GBC) agents. There are five GBC agents …